The  	The  	 DT	O
JUPITER  	JUPITER  	 NNP	B-NP
trial 	trial 	 NN	I-NP
:  	:  	 :	O
a  	a  	 DT	O
new  	new  	 JJ	O
approach  	approach  	 NN	O
in  	in  	 IN	O
primary  	primary  	 JJ	B-NP
prevention  	prevention  	 NN	I-NP
Current  	Current  	 JJ	I-NP
practice  	practice  	 NN	I-NP
guidelines  	guidelines  	 NNS	I-NP
recommend  	recommend  	 VBP	O
that 	that 	 RB	O
,  	,  	 ,	O
when  	when  	 WRB	O
determining  	determining  	 VBG	B-NP
target  	target  	 NN	I-NP
LDL-cholesterol  	LDL-cholesterol  	 JJ	I-NP
levels  	levels  	 NNS	I-NP
in  	in  	 IN	O
individuals  	individuals  	 NNS	O
without  	without  	 IN	O
cardiovascular  	cardiovascular  	 JJ	B-NP
disease  	disease  	 NN	I-NP
and  	and  	 CC	O
diabetes 	diabetes 	 NN	O
,  	,  	 ,	O
global  	global  	 JJ	O
risk  	risk  	 NN	B-NP
estimation  	estimation  	 RB	I-NP
be  	be  	 VB	O
made  	made  	 VBN	O
taking  	taking  	 VBG	O
into  	into  	 IN	O
account  	account  	 NN	B-NP
age 	age 	 NN	I-NP
,  	,  	 ,	O
sex 	sex 	 NN	O
,  	,  	 ,	O
total  	total  	 JJ	B-NP
cholesterol  	cholesterol  	 NN	I-NP
level 	level 	 NN	I-NP
,  	,  	 ,	O
HDL-cholesterol  	HDL-cholesterol  	 JJ	B-NP
level 	level 	 NN	I-NP
,  	,  	 ,	O
smoking  	smoking  	 NN	O
status 	status 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
systolic  	systolic  	 JJ	B-NP
blood  	blood  	 NN	I-NP
pressure 	pressure 	 NN	I-NP
.  	.  	 .	O
Based  	Based  	 VBN	O
on  	on  	 IN	O
this  	this  	 DT	O
assessment 	assessment 	 NN	O
,  	,  	 ,	O
target  	target  	 NN	B-NP
LDL-cholesterol  	LDL-cholesterol  	 JJ	I-NP
levels  	levels  	 NNS	I-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
set  	set  	 VBN	O
as  	as  	 IN	O
< 	< 	 SYM	O
100  	100  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
dL 	dL 	 NN	I-NP
,  	,  	 ,	O
< 	< 	 SYM	O
130  	130  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
dL 	dL 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
< 	< 	 SYM	O
160  	160  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
dL  	dL  	 NN	I-NP
for  	for  	 IN	O
high- 	high- 	 NNP	O
,  	,  	 ,	O
intermediate- 	intermediate- 	 NNP	O
,  	,  	 ,	O
and  	and  	 CC	O
low-risk  	low-risk  	 JJ	B-NP
individuals 	individuals 	 NNS	I-NP
,  	,  	 ,	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
The  	The  	 DT	O
most  	most  	 RBS	O
important  	important  	 JJ	O
rationale  	rationale  	 NN	O
for  	for  	 IN	O
this  	this  	 DT	O
approach  	approach  	 NN	O
is  	is  	 VBZ	O
to  	to  	 TO	O
implement  	implement  	 VB	O
a  	a  	 DT	O
cost-effective  	cost-effective  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
strategy 	strategy 	 NN	I-NP
,  	,  	 ,	O
giving  	giving  	 VBG	O
special  	special  	 JJ	O
attention  	attention  	 NN	O
to  	to  	 TO	O
high-risk  	high-risk  	 JJ	B-NP
individuals  	individuals  	 NNS	I-NP
when  	when  	 WRB	O
allocating  	allocating  	 VBG	O
available  	available  	 JJ	O
sources 	sources 	 NNS	O
.  	.  	 .	O
Recent  	Recent  	 JJ	O
data  	data  	 NNS	O
suggest  	suggest  	 VBP	O
that  	that  	 IN	O
increased  	increased  	 JJ	O
levels  	levels  	 NNS	O
of  	of  	 IN	O
high  	high  	 JJ	B-NP
sensitive  	sensitive  	 JJ	I-NP
C-reactive  	C-reactive  	 JJ	I-NP
protein  	protein  	 NN	I-NP
( 	( 	 -LRB-	O
hs-CRP 	hs-CRP 	 NNP	B-NP
)  	)  	 -RRB-	O
are  	are  	 VBP	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
increased  	increased  	 JJ	O
risk  	risk  	 NN	O
for  	for  	 IN	O
cardiovascular  	cardiovascular  	 JJ	B-NP
events 	events 	 NNS	I-NP
,  	,  	 ,	O
independent  	independent  	 JJ	O
of  	of  	 IN	O
other  	other  	 JJ	O
risk  	risk  	 NN	B-NP
parameters 	parameters 	 NNS	I-NP
.  	.  	 .	O
Most  	Most  	 RBS	O
recently 	recently 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
JUPITER  	JUPITER  	 NNP	B-NP
trial  	trial  	 NN	I-NP
demonstrated  	demonstrated  	 VBN	O
that  	that  	 IN	O
rosuvastatin  	rosuvastatin  	 CD	B-NP
20  	20  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
day  	day  	 NN	I-NP
significantly  	significantly  	 RB	O
lowered  	lowered  	 VBD	O
cardiovascular  	cardiovascular  	 JJ	B-NP
mortality  	mortality  	 NN	I-NP
and  	and  	 CC	O
all-cause  	all-cause  	 JJ	B-NP
mortality  	mortality  	 NN	I-NP
in  	in  	 IN	O
low-  	low-  	 JJ	O
or  	or  	 CC	O
intermediate-risk  	intermediate-risk  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
whose  	whose  	 WP$	O
LDL-cholesterol  	LDL-cholesterol  	 JJ	B-NP
levels  	levels  	 NNS	I-NP
were  	were  	 VBD	O
< 	< 	 SYM	O
130  	130  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
dL  	dL  	 NNS	I-NP
( 	( 	 -LRB-	O
median  	median  	 JJ	B-NP
108  	108  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
dL 	dL 	 NN	I-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
hs-CRP  	hs-CRP  	 JJ	B-NP
levels  	levels  	 NNS	I-NP
were  	were  	 VBD	O
= 	= 	 CD	O
/ 	/ 	 CD	O
> 	> 	 CD	O
2  	2  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
L 	L 	 NNP	I-NP
.  	.  	 .	O
As  	As  	 IN	O
the  	the  	 DT	O
current  	current  	 JJ	O
guidelines  	guidelines  	 NNS	O
do  	do  	 VBP	O
not  	not  	 RB	O
recommend  	recommend  	 VB	O
statin  	statin  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
for  	for  	 IN	O
this  	this  	 DT	O
patient  	patient  	 JJ	O
group 	group 	 NN	O
,  	,  	 ,	O
these  	these  	 DT	O
results  	results  	 NNS	O
have  	have  	 VBP	O
caused  	caused  	 VBN	O
a  	a  	 DT	O
widespread  	widespread  	 JJ	O
interest 	interest 	 NN	O
,  	,  	 ,	O
giving  	giving  	 VBG	B-NP
rise  	rise  	 NN	I-NP
to  	to  	 TO	O
arguments  	arguments  	 NNS	O
about  	about  	 IN	O
the  	the  	 DT	O
effectiveness  	effectiveness  	 NN	O
of  	of  	 IN	O
primary  	primary  	 JJ	B-NP
prevention  	prevention  	 NN	I-NP
recommendations  	recommendations  	 NNS	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
guidelines 	guidelines 	 NNS	O
.  	.  	 .	O
This  	This  	 DT	O
review  	review  	 NN	O
aims  	aims  	 VBZ	O
to  	to  	 TO	O
discuss  	discuss  	 VB	O
the  	the  	 DT	O
results  	results  	 NNS	O
and  	and  	 CC	O
implications  	implications  	 NNS	B-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
JUPITER  	JUPITER  	 NNP	I-NP
trial 	trial 	 NN	I-NP
.  	.  	 .	O
